The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Jan. 16, 2018

Filed:

Jul. 14, 2017
Applicant:

Quark Pharmaceuticals, Inc., Fremont, CA (US);

Inventors:

Elizabeth C. Squiers, Half Moon Bay, CA (US);

Shai Erlich, Concord, CA (US);

Daniel Rothenstein, Ramat Hasharon, IL;

Nir Sharon, Jerusalem, IL;

Daniel J. Odenheimer, Potomac, MD (US);

Elena Feinstein, Rehovot, IL;

Assignee:

Quark Pharmaceuticals, Inc., Fremont, CA (US);

Attorney:
Int. Cl.
CPC ...
C12N 15/11 (2006.01); C12N 15/113 (2010.01); A61K 31/713 (2006.01); A61K 45/06 (2006.01); A61K 9/00 (2006.01);
U.S. Cl.
CPC ...
C12N 15/1135 (2013.01); A61K 9/0019 (2013.01); A61K 31/713 (2013.01); A61K 45/06 (2013.01); C12N 2310/14 (2013.01); C12N 2310/317 (2013.01); C12N 2310/319 (2013.01); C12N 2310/321 (2013.01); C12N 2310/3515 (2013.01); C12N 2320/30 (2013.01);
Abstract

The invention, in some embodiments, relates to compounds and methods for the prevention of ischemia reperfusion injury (IRI) in organs, and in particular to IRI in organs aged 35 years and older. Specific uses include prevention of IRI in native organs in vivo, in reimplantations and in transplantations of donor organs aged 35 years and older. Additional embodiments include the prophylaxis of delayed graft function (DGF) and reduction in the frequency, amount and duration of dialysis in recipients of deceased donor kidney transplantations. The methods entail contacting the organ in vivo or ex vivo with a temporary p53 inhibitor. Novel temporary dsNA p53 inhibitors are further provided.


Find Patent Forward Citations

Loading…